# Transplant Administrative Survey

***2024 Update Note****: Fields duplicative of questions validated by FACT Accreditation or those that were deemed non-critical to the RFI have been removed for the 2024 RFI cycle.*

1. Provide the name and address of the institution or corporation responsible for the provision of transplant services.

**Legal Name:**

**Name as appears on CIBMTR Center Specific Outcomes Report (if different):**

 **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Street Address:**

**City:**

**State:**  **Zip**:

**Hospital Tax ID Number:**

Program Clinical Director Email:

**Program Administrative Director Email:**

**2. Are there transplant-associated clinical services being provided at locations other**

**than the one named above?** Yes [ ]  No [ ]

If yes, please explain:

## 3. Clinical programs available (mark all that apply):

|  |  |  |
| --- | --- | --- |
| Therapy Type | Adult | Pediatric |
| Allogeneic Matched Related |  |  |
| Allogeneic Haplo Related |  |  |
| Allogeneic Unrelated - PBSC |  |  |
| Allogeneic Unrelated - Marrow |  |  |
| Allogeneic Unrelated - Cord blood |  |  |
| Autologous - Marrow |  |  |
| Autologous - PBSC |  |  |
| Autologous/Autologous Tandem |  |  |
| Autologous/Allogeneic Tandem |  |  |

If services are provided to both adult and pediatric patients, indicate program type:

 [ ]  Separate programs [ ]  Combined program

## 4. Does your institution have the following facilities and services available either directly or via contract/referred services:

| **Special Inpatient and Outpatient Facilities:** | **Yes** | **No** | **# Beds** |
| --- | --- | --- | --- |
| BMT Unit | [ ]  | [ ]  |  |
| Medical Intensive Care Unit | [ ]  | [ ]  |  |
| Surgical Intensive Care Unit | [ ]  | [ ]  |  |
| Pediatric Intensive Care Unit | [ ]  | [ ]  |  |
| Neurological Intensive Care Unit | [ ]  | [ ]  |  |
| General Pediatric Unit | [ ]  | [ ]  |  |
| BMT Clinic | [ ]  | [ ]  |  |
| Home Health Transplant Nursing Specialists | [ ]  | [ ]  |  |
| **Are the following available 24 hours/day, 7 days/week at your institution?** | **Yes** | **No** |
| Anesthesiology | [ ]  | [ ]  |  |
| Pathology | [ ]  | [ ]  |  |
| Blood banking | [ ]  | [ ]  |  |
| Renal dialysis | [ ]  | [ ]  |  |
| Operating rooms | [ ]  | [ ]  |  |
| Emergency clinical care | [ ]  | [ ]  |  |

**If “no” to any of the above, please explain:**

|  |  |  |
| --- | --- | --- |
| 5. Are housing accommodations available for patient(s)/companion(s) throughout the treatment process? | Yes [ ]  | No [ ]  |
|  |  |  |

If yes, list and provide information:

# Part A: General Information

**A-1. Accreditation / certification\***

 Current Accreditation Effective Date Applied for Date

FACT – Clinical Program

 Adult Autologous Yes [ ]  No [ ]  or Yes [ ]  No [ ]

 Adult Allogeneic Yes [ ]  No [ ]  or Yes [ ]  No [ ]

 Pediatric Autologous Yes [ ]  No [ ]  or Yes [ ]  No [ ]

 Pediatric Allogeneic Yes [ ]  No [ ]  or Yes [ ]  No [ ]

FACT – Collection Program Yes [ ]  No [ ]  or Yes [ ]  No [ ]

FACT – Cell Processing Program Yes [ ]  No [ ]  or Yes [ ]  No [ ]

FACT – Immune Effector Cell Program Yes [ ]  No [ ]  or Yes [ ]  No [ ]

NMDP Approved Date

 Apheresis Donor Center Yes [ ]  No [ ]

 Marrow Donor Center Yes [ ]  No [ ]

 Transplant Center Yes [ ]  No [ ]

Cell Therapy Laboratory Approved Date

 CAP Yes [ ]  No [ ]

 CLIA Yes [ ]  No [ ]

 AABB Yes [ ]  No [ ]

Medicare Provider Yes [ ]  No [ ]

State-Sponsored Provider Yes [ ]  No [ ]

\***NOTE:** ASTCT does notwarrant, guarantee, or endorse every accreditation/certification program listed above, and transplant and cell therapy centers need not obtain accreditation/certification from every program listed. Payers individually establish requirements for the inclusion of transplant centers in their networks.

**A-2. Has the Autologous Adult Program been closed or suspended for any reason during**

**the past 36 months?**

Yes [ ]  No [ ]  Not applicable [ ]

 If yes, provide dates and explain:

**Has the Autologous Pediatric Program been closed or suspended for any reason during**

**the past 36 months?**

Yes [ ]  No [ ]  Not applicable [ ]

 If yes, provide dates and explain:

**Has the Allogeneic Adult Program been closed or suspended for any reason during**

**the past 36 months?**

Yes [ ]  No [ ]  Not applicable [ ]

If yes, provide dates and explain:

**Has the Allogeneic Pediatric Program been closed or suspended for any reason during**

**the past 36 months?**

Yes [ ]  No [ ]  Not applicable [ ]

If yes, provide dates and explain:

**A-3. How does the Program provide the following transplant-related services?**

Mobilization therapy [ ]  inpatient [ ]  outpatient [ ]  both

Marrow Harvest [ ]  inpatient [ ]  outpatient [ ]  both

PBSC Apheresis [ ]  inpatient [ ]  outpatient [ ]  both

Conditioning Regimens [ ]  inpatient [ ]  outpatient [ ]  both

Marrow/Stem Cell Infusion [ ]  inpatient [ ]  outpatient [ ]  both

Recovery [ ]  inpatient [ ]  outpatient [ ]  both

**A-4. Does the Program perform the following?**

 Donor leukocyte infusions Yes [ ]  No [ ]

 Cell purging Yes [ ]  No [ ]

Photopheresis Yes [ ]  No [ ]

 T-cell depletion Yes [ ]  No [ ]

 Double cord blood transplants (cord blood units infused separately)? Yes [ ]  No [ ]

Pooled cord blood transplants (cord blood units combined for infusion)?Yes [ ]  No [ ]

Does the Program have any protocols that involve planned tandem/multiple cycles of high dose chemotherapy followed by hematopoietic stem cell infusion:

Autologous / Autologous Yes [ ]  No [ ]

Autologous / Allogeneic (ablative or non-myeloablative) Yes [ ]  No [ ]

Other planned multiple sequential infusions of autologous stem cells Yes [ ]  No [ ]

#### A-5. Number of Patients Receiving Planned Tandem/Sequential Transplants

Tandem transplant is defined as receiving two cycles of chemotherapy (high dose or immunosuppressive) with progenitor cell support. The second course of therapy and stem cell infusion is planned in advance, at the time of planning for the first course of therapy and stem cell infusion. Report the patient in the year in which the **first** transplant was performed.

**Autologous Transplant followed by Autologous Transplant(s)**, including Tandem/Sequential:

|  |  |
| --- | --- |
| Disease | Number of patients receiving tandem/sequential transplants |
| **2020** | **2021** | **2022** | **2023** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

 **Autologous Transplant followed by Allogeneic Transplant**:

|  |  |
| --- | --- |
| Disease | Number of patients receiving tandem transplants |
| **2020** | **2021** | **2022** | **2023** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

**A-6. Number of Transplant Procedures Performed**

**Record the total number of transplant procedures performed in the years indicated. Categories are mutually exclusive. Do not include DLIs or stem cell boosts. Antigens to be used are Class I + DRB1 (the denominator is 8 antigens). Patients with multiple transplants will be counted more than once.**

**Adult (greater than or equal to 18 years of age):**

| **Transplant Type** | **2020** | **2021** | **2022** | **2023** |
| --- | --- | --- | --- | --- |
| **Autologous** |  |  |  |  |
| **Allogeneic Myeloablative Related Donor:** |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Non-myeloablative Related Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Myeloablative Unrelated Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Non-myeloablative Unrelated Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| **Cord Blood** |  |  |  |  |
| Total |  |  |  |  |

**Pediatric (less than 18 years of age):**

| **Transplant Type** | **2020** | **2021** | **2022** | **2023** |
| --- | --- | --- | --- | --- |
| **Autologous** |  |  |  |  |
| **Allogeneic Myeloablative Related Donor:** |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Non-myeloablative Related Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Myeloablative Unrelated Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Non-myeloablative Unrelated Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| **Cord Blood** |  |  |  |  |
| Total |  |  |  |  |

**A-7. Number of Patients Transplanted by Age**

Performed from 1/1 through 12/31 of the most recent calendar year only. Antigens to be used are Class I + DRB1 (the denominator is 8 antigens). Do not include DLIs or stem cell boosts.

| **Transplant Type** | **0-10** | **11-17** | **18-64** | **65+** |
| --- | --- | --- | --- | --- |
| **Autologous** |  |  |  |  |
| **Allogeneic Myeloablative Related Donor:** |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Non-myeloablative Related Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Myeloablative Unrelated Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| Non-myeloablative Unrelated Donor: |  |  |  |  |
|  0 Antigen Mismatch |  |  |  |  |
|  1 Antigen Mismatch |  |  |  |  |
|  > 1 Antigen Mismatch |  |  |  |  |
| **Cord Blood** |  |  |  |  |
| Total |  |  |  |  |

**A-8. Number of Patients Receiving Retransplantation**

A retransplant is defined as a second transplant occurring within 365 days of the first transplant for the same indication for which the first transplant was performed. The retransplant is performed due to graft failure or due to disease progression within 365 days of the first transplant. Report the patient in the year in which the **second** transplant was performed.

|  |  |  |
| --- | --- | --- |
| Retransplantation | **Due to graft failure** | **Due to disease progression** |
| **2020** | **2021** | **2022** | **2023** | **2020** | **2021** | **2022** | **2023** |
| Number of patients |  |  |  |  |  |  |  |  |

**Part B: Protocols**

**B-1. Patient Selection**

a)Describe the patient selection processes utilized by the Program (patient selection committee, frequency with which it meets, who attends, are minutes taken, etc).

Describe protocols for patient selection, including indications and contraindications for adult and pediatric autologous and allogeneic transplantation. Include the match criteria for allogeneic transplants.

b) Are all patients managed under a protocol (either research or institutional standard of care)?

Yes [ ]  No [ ]

 If treatments are performed “off protocol,” how is the decision made?

**B-2. Describe patient and family support services provided throughout the transplant process.**

**B-3. Describe patient education provided throughout the transplant process.**

**B-4. Is a patient satisfaction survey used by the Program?** Yes [ ]  No [ ]

**B-5. Is the Program affiliated with the NCI and/or other** Yes [ ]  No [ ]

 **cooperative clinical research groups?**

 If yes, please list which groups.

**B-6.** **Data Reporting to the CIBMTR**

Does the Program report its allogeneic transplant data? Yes [ ]  No [ ]

Does the Program report its autologous transplant data? Yes [ ]  No [ ]

**B-7 Provide a list of research and treatment protocols in which transplant patients may be enrolled. Include protocol title, inclusion criteria and exclusion criteria, objectives, type of protocol (e.g. multi-center, pharmaceutical, institutional), and if not included in the title, induction agents and the protocol Phase. You may include the protocol’s executive summary.**

**(continues on next page)**

**Part C: Program Teams**

**C-1. Adult Transplant Team Composition**

| **Name** | **Board Certification / Specialty** | **Years of experience actively managing transplant patients****Allo Auto** | **Became a member of this team****Month / Year** |
| --- | --- | --- | --- |
| **Program Clinical Director:** |  |  |  |  |
|  |  |  |  |  |
| **Program Administrative Director:** |  |  |  |  |
|  |  |  |  |  |
| **Transplant Physician(s):** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Transplant Clinical Coordinator(s)** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Social Service:** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Financial Coordinator:** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Data Coordinator(s):** |  |  |  |  |
|  |  |  |  |  |
| **Clinical PharmD and/or Pharmacist(s):** |  |  |  |  |
|  |  |  |  |  |
| **Other** |  |  |  |  |

**Have there been any changes in medical leadership of the Adult Program in the past 12 months?**  Yes [ ]  No [ ]

If yes, provide date(s) and explain.

**C-2. Pediatric Transplant Team Composition**

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** | **Board Certification / Specialty** | **Years of experience actively managing transplant patients****Allo Auto** | **Became a member of this team****Month / Year** |
| **Program Clinical Director:** |  |  |  |  |
|  |  |  |  |  |
| **Program Administrative Director:** |  |  |  |  |
|  |  |  |  |  |
| **Transplant Physician(s):** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Transplant Clinical Coordinator(s):** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Social Service**: |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Child Life**: |  |  |  |  |
|  |  |  |  |  |
| **Financial Coordinator:** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Data Coordinator**: |  |  |  |  |
|  |  |  |  |  |
| **Clinical PharmD and/or Pharmacist(s):** |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Other:**  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

**Have there been any changes in medical leadership of the Pediatric Program**

**in the past 12 months?**  Yes [ ]  No [ ]

If yes, provide date(s) and explain:

**Part D: Quality**

**D-1. Attach your most recent FACT Quality Management Program Description (e.g. metrics monitored). Detailed plans with actual variances are not requested.**

**Part E: Summary Information**

**E-1. Describe the Program’s unique qualities**.

**E-2. Provide any additional information that you feel is important regarding the Program**.

# Part F: Outcomes Data

Report outcomes data using the RFI-associated excel spreadsheets. Please review the Definitions tab of the spreadsheet prior to completion of the outcome data tables.

I have investigated and certify that the information contained in this survey and all attachments is accurate, complete, and true.

I understand that submission of this survey does not automatically result in participation or continued participation.

Name Signature

Title Program Administrative Director Date

Name Signature

Title Program Clinical Director Date